Boxer Capital’s Protara Therapeutics TARA Stock Holding History

Boxer Capital’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-811,627	Closed	-$1.49M	–	55
2024 Q3	$1.49M	Hold	811,627	–	–	0.07%	61
2024 Q2	$1.69M	Buy	811,627 +602,400	+288%	+$1.76M	0.09%	55
2024 Q1	$839K	Hold	209,227	–	–	0.04%	55
2023 Q4	$392K	Hold	209,227	–	–	0.02%	49
2023 Q3	$349K	Hold	209,227	–	–	0.02%	70
2023 Q2	$500K	Hold	209,227	–	–	0.02%	75
2023 Q1	$655K	Hold	209,227	–	–	0.03%	72
2022 Q4	$561K	Hold	209,227	–	–	0.03%	67
2022 Q3	$619K	Hold	209,227	–	–	0.03%	68
2022 Q2	$613K	Hold	209,227	–	–	0.04%	72
2022 Q1	$1.07M	Hold	209,227	–	–	0.05%	71
2021 Q4	$1.41M	Hold	209,227	–	–	0.05%	68
2021 Q3	$1.45M	Hold	209,227	–	–	0.05%	84
2021 Q2	$2.04M	Hold	209,227	–	–	0.07%	89
2021 Q1	$3.29M	Hold	209,227	–	–	0.11%	77
2020 Q4	$5.07M	Hold	209,227	–	–	0.16%	69
2020 Q3	$3.52M	Hold	209,227	–	–	0.12%	71
2020 Q2	$6.13M	Buy	209,227 +9,660	+5%	+$299K	0.27%	54
2020 Q1	$4.59M	Buy	+199,567	New	+$5.81M	0.31%	48

Other funds holding TARA

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital's TARA Position: Q4 2024 in Review

Boxer Capital sold out of Protara Therapeutics (TARA) in Q4 2024, closing a stake of 811,627 shares — an estimated $1.49M sold.

Boxer Capital first reported a position in TARA in Q1 2020 and held it in 19 quarters. The position peaked at $6.13M in Q2 2020. 60 funds tracked by Wall St. Rank hold TARA as of Q4 2024.

Boxer Capital reported no remaining Protara Therapeutics position as of Q4 2024 after selling out during the quarter.
Boxer Capital sold 811,627 Protara Therapeutics shares in Q4 2024, an estimated $1.49M.
Boxer Capital first reported a position in Protara Therapeutics in Q1 2020 and held it in 19 quarters.
Boxer Capital's Protara Therapeutics position peaked at $6.13M in Q2 2020.
60 funds tracked by Wall St. Rank held Protara Therapeutics as of Q4 2024.

Based on Boxer Capital's 13F filing for Q4 2024.